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Anatomy and Genetics, University of Oxford, Oxford, United KingdomGlomerular disease is characterized by morphologic
changes in podocyte cells accompanied by inﬂammation
and ﬁbrosis. Thymosin b4 regulates cell morphology,
inﬂammation, and ﬁbrosis in several organs and
administration of exogenous thymosin b4 improves animal
models of unilateral ureteral obstruction and diabetic
nephropathy. However, the role of endogenous thymosin
b4 in the kidney is unknown. We demonstrate that
thymosin b4 is expressed prominently in podocytes of
developing and adult mouse glomeruli. Global loss of
thymosin b4 did not affect healthy glomeruli, but
accelerated the severity of immune-mediated nephrotoxic
nephritis with worse renal function, periglomerular
inﬂammation, and ﬁbrosis. Lack of thymosin b4 in
nephrotoxic nephritis led to the redistribution of podocytes
from the glomerular tuft toward the Bowman capsule
suggesting a role for thymosin b4 in the migration of these
cells. Thymosin b4 knockdown in cultured podocytes also
increased migration in a wound-healing assay,
accompanied by F-actin rearrangement and increased
RhoA activity. We propose that endogenous thymosin b4 is
a modiﬁer of glomerular injury, likely having a protective
role acting as a brake to slow disease progression.
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1056E nd-stage renal failure is a devastating conditionrequiring lifelong dialysis and transplantation and a riskfactor for all-cause mortality and cardiovascular
disease.1 Many cases are due to disruption of the glomerular
ﬁltration barrier, consisting of epithelial podocytes, the endo-
thelium, the mesangium, and the glomerular basement mem-
brane.2 Podocytes have a unique shape maintained by a
complex cytoskeleton,3 with branched foot process extensions
that abut each other at slit diaphragms. During glomerular
injury, the podocyte architecture is perturbed, resulting in
defective ﬁltration and proteinuria,2–4 often with inﬂamma-
tory components characterized by leukocyte inﬁltration fol-
lowed by glomerulosclerosis and tubulointerstitial ﬁbrosis.5
Thymosin b4 (Tmsb4x) is a naturally occurring peptide. It
is the major G-actin sequestering protein in mammalian
cells,6 with critical roles in maintaining the cell cytoskeleton.
In animal models, exogenous Tmsb4x has beneﬁcial effects in
diverse pathologies including myocardial infarction,7 stroke,8
dry eye,9 and inﬂammatory lung disease,10 and there are
clinical trials assessing Tmsb4x treatment in wound healing
and cardioprotection.11 The utility of Tmsb4x in these pa-
thologies has been attributed to modulation of several cellular
functions including cell motility,12 differentiation,13 sur-
vival,14 angiogenesis,15 inﬂammation,16 and ﬁbrosis.10
Recent studies investigated exogenous Tmsb4x as a treat-
ment for kidney disease.17 Tmsb4x reduced renal tubu-
lointerstitial ﬁbrosis after unilateral ureteral obstruction in
mice, potentially through decreasing plasminogen activator
inhibitor-1 expression and dampening transforming growth
factor-b1 signaling.
18 In KK Cg-Ay/J mice, a model of type 2
diabetes mellitus, daily Tmsb4x treatment for 3 months
reduced albuminuria and attenuated renal pathology.19
Furthermore, N-acetyl-seryl-aspartyl-lysyl-proline, the
N-terminal tetrapeptide generated by Tmsb4x cleavage,20 has
beneﬁcial effects on ﬁbrosis and inﬂammation in unilateral
ureteral obstruction, remnant kidneys, diabetic nephropathy,
and glomerulonephritis.18,21–23
Tmsb4x transcripts are detectable by in situ hybridization in
developing and adult glomeruli,24 with strong expression in
podocytes.24,25 Furthermore, in rat remnant kidneys, proteo-
mic analysis of laser-capture dissected glomeruli demonstratedKidney International (2016) 90, 1056–1070
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glomeruli.26 Despite such evidence of expression and beneﬁcial
renal effects, the functional importance of endogenous Tmsb4x
in the kidney during health and disease is completely unknown.
In this study, we conﬁrmed that Tmsb4x is highly
expressed in the kidney glomerulus, predominantly in
podocytes. Using global Tmsb4x knockout mice,27 we
demonstrated that endogenous Tmsb4x was dispensable in
healthy glomeruli. Furthermore, in an experimental model of
glomerular damage, lack of Tmsb4x worsened disease pro-
gression by (i) enhancing podocyte migration, facilitating
their redistribution from the glomerular tuft to the Bowman
capsule, and (ii) increasing periglomerular inﬂammation and
interstitial ﬁbrosis. Thus, we provide the ﬁrst evidence that
endogenous Tmsb4x is critical in the progression of glomer-
ular disease.
RESULTS
Tmsb4x is expressed in mouse glomerular podocytes
Tmsb4x mRNA levels were assessed in the spleen, liver, heart,
and whole kidney of healthy adult mice. The highest tran-
script levels were found in the spleen with w10 times less
Tmsb4x in the kidney (Figure 1a). Using Dynabead perfusion
(Thermo Fisher Scientiﬁc, Waltham, MA),28 we isolated
glomeruli and found that Tmsb4x levels were signiﬁcantly
enriched in glomeruli compared with the rest of the kidney
(Figure 1a). In situ hybridization detected Tmsb4x expression
in immature glomeruli of embryonic day 16.5 developing
kidneys, predominantly in podocytes (Figure 1b and c). The
protein expression of Tmsb4x was also assessed by immu-
nohistochemistry, and we found strong localization in
glomerular podocytes at embryonic day 18 (Figure 1d). This
expression pattern was maintained in 1-week-old postnatal
(Figure 1e) and 8-week-old adult kidneys (Figure 1f). Tmsb4x
podocyte expression was further conﬁrmed by colocalization
of Tmsb4x with nephrin (Nphs1), a slit diaphragm compo-
nent29 (Figure 1g–i), and nestin, an intermediate ﬁlament
protein expressed in mature podocytes30 (Supplementary
Figure S1A–C). In contrast, Tmsb4x did not colocalize with
the pan-endothelial marker Cd31 (Supplementary
Figure S1D–F).
Lack of endogenous Tmsb4x has no effect on healthy
glomeruli
We examined mice with a global loss of Tmsb4x27 to assess the
importance of endogenous Tmsb4x in healthy glomeruli. As
Tmsb4x is mapped to the X chromosome,31 we crossed
hemizygous null male mice (Tmsb4x/y) with heterozygous
Tmsb4xþ/ adult female mice (Figure 2a). We found no lethal
developmental abnormalities with the offspring conforming
to Mendelian ratios (Supplementary Table S1). Tmsb4x/y
mice had albumin excretion (Figure 2b) and blood urea ni-
trogen (Figure 2c) levels similar to those of male wild-type
Tmsb4xþ/y mice at the ages of 1, 3, and 6 months. There
was no difference in body weight at 1 (Tmsb4xþ/y ¼ 23.8 
0.7 g; Tmsb4x/y ¼ 23.4  0.4 g), 3 (Tmsb4xþ/y ¼ 30.0  0.5Kidney International (2016) 90, 1056–1070g; Tmsb4x/y ¼ 29.2  0.7 g), or 6 (Tmsb4xþ/y ¼ 35.8  1.0 g;
Tmsb4x/y ¼ 35.3  1.6 g) months of age. Using semi-
quantitative analysis of light microscopy images, we found no
differences in glomerular morphology between 6-month-old
Tmsb4xþ/y and Tmsb4x/y mice (Figure 2d–f). This was
conﬁrmed by transmission electron microscopy with normal
foot process architecture, laminar structure of the basement
membrane, and the presence of endothelial fenestrae in both
Tmsb4xþ/y and Tmsb4x/y mice (Figure 2g and h). We
demonstrated the loss of Tmsb4x protein in glomeruli of
Tmsb4x/y mice compared with Tmsb4xþ/y (Figure 2i and j),
along with undetectable Tmsb4x mRNA levels in whole kid-
neys (Figure 2k). We examined whether there was any
compensation for the lack of Tmsb4x by other b-thymosins,
but found no changes in the renal mRNA levels of Tmsb10,
Tmsb15a, Tmsb15b, and Tmsb15l (Figure 2l–o). We also
assessed mRNA levels of genes involved in actin polymeri-
zation and found no differences in proﬁlin (Pfn) 1 and 2 and
destrin (Dstn) between Tmsb4x/y and Tmsb4xþ/y mice
(Supplementary Figure S2A–C). In contrast, coﬁlin 1 (Cﬂ1)
mRNA levels were signiﬁcantly increased in Tmsb4x/y kid-
neys by w30% compared with Tmsb4xþ/y mice
(Supplementary Figure S2D). We speciﬁcally examined Cﬂ1
mRNA levels in podocytes and found no change after knock
down of endogenous Tmsb4x by small, interfering RNA
(siRNA) (Supplementary Figure S2E). Furthermore, there was
no difference in Cﬂ1 mRNA levels in primary podocytes
isolated from Tmsb4x/y and Tmsb4xþ/y mice (Supplementary
Figure S2F). Finally, the mRNA levels of genes important for
podocyte function (Nphs1, Nphs2, Synpo, Cd2ap, and Wt1)
were unchanged in Tmsb4x/y and Tmsb4xþ/y kidneys
(Supplementary Figure S3A–E).
Lack of endogenous Tmsb4x worsens renal function and
glomerular injury in nephrotoxic serum nephritis
Our results suggest that the lack of Tmsb4x does not affect the
function and morphology of healthy glomeruli. Therefore, we
investigated whether Tmsb4x has a role in glomerular disease.
We utilized the nephrotoxic serum (NTS) nephritis model,
which replicates some of the pathologic features of human
crescentic glomerulonephritis.32 NTS nephritis involves the
injury of intrinsic glomerular cells, including podocytes, as well
as leukocyte inﬁltration, glomerulosclerosis, and tubulointer-
stitial ﬁbrosis,33 processes in which Tmsb4x has been impli-
cated.10,16 We predicted that the lack of global Tmsb4x may
exacerbate NTS nephritis severity and examined this in
3-month-old Tmsb4x/y and Tmsb4xþ/y mice (Figure 3a).
Albuminuria and the albumin/creatinine ratio were signiﬁ-
cantly increased in Tmsb4xþ/y mice 21 days after NTS admin-
istration compared with the levels before immunization (P <
0.001 in both cases) (Figure 3b and c). Strikingly, both albu-
minuria and the albumin/creatinine ratio were further
enhanced by w5- and 7-fold, respectively, when NTS was
injected in Tmsb4x/y mice compared with Tmsb4xþ/y mice
(P < 0.01 in both cases) (Figure 3b and c). Administration of
NTS to Tmsb4x/y mice also signiﬁcantly increased plasma1057
Figure 1 | Tmsb4x expression in the mouse glomerulus. (a) Quantiﬁcation of thymosin b4 (Tmsb4x) mRNA levels in adult mouse spleen, liver,
heart, and kidney by quantitative reverse transcriptase polymerase chain reaction. Tmsb4x expression was also quantiﬁed in glomeruli-depleted
[glom (-)] and glomeruli-enriched [glom (þ)] kidney homogenates. The bars represent the mean of 3 samples  SEM. (b,c) In situ hybridization
for Tmsb4x on embryonic day (E) 16.5 mouse kidney sections. Cells positive for Tmsb4x are indicated by arrows. Immunohistochemistry for
Tmsb4x in the mouse glomerulus at E18 (d), 1 week (e), and 8 weeks (f) of age. Cells positive for Tmsb4x are indicated by arrows. Representative
images of Tmsb4x (g) and nephrin (Nphs1) (h) staining in the mouse adult wild-type glomerulus visualized by ﬂuorescent microscopy. (i)
Merged images showing Nphs1 (red) and Tmsb4x (green) staining; areas of colocalization are indicated by arrows. Bar ¼ 20 mm. **P # 0.01.
bas i c re sea r ch E Vasilopoulou et al.: Thymosin b4 and glomerular diseasecreatinine (P< 0.01) (Figure 3d), impaired creatinine clearance
(P< 0.01) (Figure 3e), and raised the blood urea nitrogen level
(P < 0.05) (Figure 3f) compared with Tmsb4xþ/y mice with
NTS nephritis. We found no difference in Tmsb4x levels in
whole kidneys obtained from Tmsb4xþ/y mice without disease
or administered NTS (Supplementary Figure S4A). Further-
more, in kidney biopsy specimens obtained from patients with1058either rapidly progressive glomerulonephritis or lupus
nephritis, there was no change in glomerular or tubulointer-
stitial TMSB4X mRNA levels compared with living donor
control kidneys (Supplementary Figure S4B and C).
Seven days after NTS administration, we observed mild
glomerular injury in Tmsb4x/y and Tmsb4xþ/y mice, with
some glomeruli containing hyaline deposits, increasedKidney International (2016) 90, 1056–1070
Figure 2 | Renal function and glomerular morphology in Tmsb4xþ/y and Tmsb4x/y mice. (a) Breeding scheme: heterozygous female mice
(Tmsb4xþ/) were bred with hemizygous null male mice (Tmsb4x/y). Male wild-type (Tmsb4xþ/y) and Tmsb4x/y mice were compared in all
subsequent experiments. (b) Twenty-four hour albumin excretion in urine of Tmsb4xþ/y (n ¼ 14–15) and Tmsb4x/y (n ¼ 9–10) mice collected at
1, 3, and 6 months of age. Data were log-transformed before analysis. (c) Blood urea nitrogen (BUN) concentration in Tmsb4xþ/y (n ¼ 9–15) and
Tmsb4x/y mice (n ¼ 7–9) at 1, 3, and 6 months of age. Data were log-transformed before analysis. Representative images of periodic acid–Schiff
staining of parafﬁn-embedded sections from Tmsb4xþ/y (d) and Tmsb4x/y (e) kidneys. Bar ¼ 20 mm. The glomerular score (f) was quantiﬁed as
explained in the Methods section (Tmsb4xþ/y: n ¼ 4; Tmsb4x/y: n ¼ 5). Representative images of the glomerular architecture of Tmsb4xþ/y (g)
and Tmsb4x/y (h) kidneys assessed by transmission electron microscopy. An average of 5 glomeruli were examined per animal (Tmsb4xþ/y, n ¼
4; Tmsb4x/y, n ¼ 3). Representative images of immunohistochemistry for thymosin b4 (Tmsb4x) on parafﬁn-embedded sections from Tmsb4xþ/
y (i) and Tmsb4x/y (j) kidneys from 6-month-old mice. Tmsb4x-positive cells are indicated by arrows. Note: nonspeciﬁc staining in tubules in
Tmsb4xþ/y mice and Tmsb4x/y mice. Quantiﬁcation of Tmsb4x (k), Tmsb10 (l), Tmsb15a (m), Tmsb15b (n), and Tmsb15l (o) mRNA levels in whole-
kidney homogenates of Tmsb4xþ/y (n ¼ 8) and Tmsb4x/y (n ¼ 4) mice by quantitative reverse transcriptase polymerase chain reaction. Data are
presented as mean  SEM. ***P# 0.001. Bar ¼ 20 mm. EC, endothelial cell; GBM, glomerular basement membrane; HPRT, hypoxanthine-guanine
phosphoribosyltransferase; Pod, podocyte; Tmsb4x, thymosin b4; Tmsb10, thymosin b10; Tmsb15a, thymosin b15a; Tmsb15b, thymosin b15b;
Tmsb15b1, thymosin b15b-like.
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Figure 3 | Renal function in Tmsb4xþ/y and Tmsb4x/y mice after the induction of nephrotoxic nephritis. (a) Outline of experimental
strategy. Twenty-four–hour albumin excretion in urine (b), urinary albumin to urinary creatinine ratio (c), plasma creatinine concentration (d),
creatinine clearance (e), and blood urea nitrogen (BUN) concentration (f) of Tmsb4xþ/y and Tmsb4x/y mice. Samples were collected before
immunization with Freund’s adjuvant (Tmsb4xþ/y, control group) and 21 days after administration of nephrotoxic serum (NTS) (Tmsb4xþ/y þ NTS
and Tmsb4x/y þ NTS); n ¼ 12 in each group. Data were log-transformed before analysis and presented as mean  SEM. (g) Glomerular score
was quantiﬁed as described in the Methods section in Tmsb4xþ/y (n ¼ 5), Tmsb4xþ/y þ NTS (n ¼ 9), and Tmsb4x/y þ NTS (n ¼ 6) mice. Data are
presented as mean  SEM. Representative images of periodic acid–Schiff staining in glomeruli from control mice (Tmsb4xþ/y; h) and mice
administered NTS; Tmsb4xþ/y þ NTS (i) and Tmsb4x/y þ NTS (j) are shown. Bar ¼ 20 mm. *P# 0.05, **P# 0.01, ***P# 0.001. s.c., subcutaneous;
Tmsb4x, thymosin b4.
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tuft to the Bowman capsule (Supplementary Figure S5A–C).
After 21 days, there was a range of abnormalities in Tmsb4x/y1060and Tmsb4xþ/y mice injected with NTS including collapse of
capillary loops, segmental or global glomerulosclerosis,
adhesion of the glomerular tuft to the Bowman capsule, andKidney International (2016) 90, 1056–1070
E Vasilopoulou et al.: Thymosin b4 and glomerular disease ba s i c re sea r chglomerular epithelial hyperplasia lesions, a feature of early
crescent formation in this model.34 Semiquantitative histo-
logic scoring (Supplementary Figure S6A–E) by 2 blinded
observers revealed that Tmsb4xþ/y mice injected with NTS
had a signiﬁcantly increased mean glomerular score
compared with Tmsb4xþ/y mice without disease (P < 0.001)
(Figure 3g–j). Glomeruli of Tmsb4x/y administered NTS had
an even higher glomerular mean score that was signiﬁcantly
greater than that in Tmsb4xþ/y mice with NTS nephritis
(P < 0.05). This was associated with an increased proportion
of sclerotic glomeruli and an increased incidence of epithelial
hyperplasia lesions in Tmsb4x/y compared with Tmsb4xþ/y
mice administered NTS (Supplementary Figure S6F).
We examined whether the difference in disease severity
between Tmsb4x/y and Tmsb4xþ/y mice administered NTS
could be due to a decrease in binding of the antiglomerular
antibody but found no difference in the amount of sheep IgG
deposited within the glomerulus (Supplementary Figure S7A–
C). We assessed whether the lack of Tmsb4x changes the
humoral immune response to sheep IgG. NTS injection led to
signiﬁcantly increased production of circulating murine IgG1
and IgG2a, but not IgG2b or IgG3, against sheep IgG
compared with Tmsb4xþ/y mice without disease. However,
there was no difference in the plasma titers of any of the IgG
subclasses between Tmsb4x/y and Tmsb4xþ/y mice adminis-
tered NTS (Supplementary Figure S7D–G).
Changes in podocyte distribution in Tmsb4x/y glomeruli
after NTS nephritis
After NTS nephritis, we found that Tmsb4x still colocalized
with Nphs1 (Figure 4a–c) and subsequently examined the
effect that a lack of Tmsb4x had on podocytes in this model.
First, we quantiﬁed Wilms Tumor 1 postive (WT1þ) podo-
cyte numbers,35 inside and outside of the glomerular tuft
(Figure 4d–f). The number of glomerular tuft WT1þ cells was
unchanged in Tmsb4xþ/y mice after NTS injection compared
with mice without disease. However, NTS administration to
Tmsb4x/y mice signiﬁcantly reduced the number of WT1þ
glomerular tuft cells compared with Tmsb4xþ/y mice with
NTS nephritis (P < 0.001) (Figure 4g). This ﬁnding persisted
after normalizing the WT1þ cell number to the glomerular
tuft area (P < 0.05) (Figure 4h). In contrast, there was an
increased number of WT1þ cells outside the glomerular tuft
in both Tmsb4xþ/y and Tmsb4x/y mice after NTS adminis-
tration; this was more prominent and signiﬁcantly different in
the Tmsb4x/y animals (P < 0.05 compared with Tmsb4xþ/y
without disease) (Figure 4i). The total number of podocytes
in the whole glomerulus did not differ between any of the
groups (Figure 4j), suggesting that lack of Tmsb4x leads to
podocyte redistribution from the glomerular tuft toward the
Bowman capsule rather than affecting podocyte cell death. To
support this, we assessed podocyte apoptosis using terminal
deoxynucleotidyltransferase–mediated dUTP nick end-
labeling (TUNEL)36 in combination with WT1 staining
(Supplementary Figure S8A–C). Administration of NTS
increased the number of glomerular apoptotic cells comparedKidney International (2016) 90, 1056–1070with healthy mice, and this effect was signiﬁcant in Tmsb4þ/y
mice with glomerular disease (P < 0.05) (Supplementary
Figure S8D). However, the number of TUNELþ/WT1þ cells
was not signiﬁcantly different between any of the groups
(Supplementary Figure S8E).
Lack of Tmsb4x induces migration and modulates the cyto-
skeleton of podocytes in vitro
We postulated that the redistribution of podocytes in neph-
rotoxic nephritis may be due to changes in cell migration
driven by lack of Tmsb4x. Therefore, we transfected cultured
differentiated mouse podocytes37 with siRNA against Tmsb4x
(Figure 5a); this resulted in >90% knockdown in Tmsb4x
levels (Figure 5b) (P < 0.001). Knockdown of endogenous
Tmsb4x did not affect podocyte viability (Figure 5c) but
increased the number of cells that migrated into the wound
area in a wound-healing assay (P < 0.05) (Figure 5d and e).
Because the cytoskeleton is essential for cell movement,38 we
visualized podocyte actin by phalloidin staining and classiﬁed
the ﬁlament organization as either cytoplasmic stress ﬁbers
(Figure 5f) or cortical actin (Figure 5g). Knockdown of
endogenous Tmsb4x signiﬁcantly increased the percentage of
cells with stress actin ﬁber organization (P < 0.001)
(Figure 5h). Finally, we assessed the effects of Tmsb4x
knockdown on the activation of RhoA and Cdc42, which
regulate actin dynamics and cell migration.39 There was
increased RhoA activity in podocytes transfected with Tmsb4x
siRNA compared with control siRNA (P < 0.05) (Figure 5i),
whereas Cdc42 activity was unaffected (Figure 5j).
Macrophage accumulation and increased ﬁbrosis in
Tmsb4x/y glomeruli after NTS nephritis
Tmsb4x is expressed in macrophages18,40 and reduces
inﬂammation in several disease settings.10,16,18,41 As immune
cell inﬁltration plays a critical role in the initiation and pro-
gression of crescentic glomerulonephritis,42–44 we decided to
examine this in the NTS nephritis model. We found expres-
sion of Tmsb4x in F4/80þ macrophages surrounding the
glomeruli and occasionally within the glomerular tuft
(Figure 6a–c) and went on to examine the effect of Tmsb4x
loss on glomerular inﬂammation in our experimental model.
We measured the number of Cd3þ (T cells) and F4/80þ
cells in Tmsb4x/y and Tmsb4xþ/y glomeruli. Twenty-one days
after NTS injection, there was a signiﬁcant increase in Cd3þ
cells in the glomerular tuft of Tmsb4x/y mice compared with
Tmsb4xþ/y mice without disease (P < 0.05) but no signiﬁcant
difference when comparing Tmsb4x/y and Tmsb4xþ/y mice
with nephrotoxic nephritis (Figure 6d–g). There was also no
difference in the number of periglomerular Cd3þ cells be-
tween experimental groups (Figure 6h). Seven days after NTS
administration, the number of F4/80þ glomerular tuft cells
was similar in all experimental groups, but were signiﬁcantly
increased in the periglomerular area of both NTS-injected
Tmsb4xþ/y and Tmsb4x/y mice compared with healthy mice
(P < 0.01) (Supplementary Figure S9A and B). The accu-
mulation of F4/80þ cells persisted in Tmsb4x/y mice 21 days1061
Figure 4 | Podocyte assessment in Tmsb4xþ/y andTmsb4x/y mice after induction of nephrotoxic nephritis. Representative image of nephrin
(Nphs1; podocytes) (a) and Tmsb4x (b) staining in the adult wild-type mouse glomerulus 21 days after injection of nephrotoxic serum (NTS). Cells
positive for bothNphs1 (green) and Tmsb4x (red) are indicatedbyarrows in themerged image (c). Representative imagesofglomeruli fromTmsb4xþ/y
(d), Tmsb4xþ/yþ NTS (e), and Tmsb4x/yþ NTS (f) mice stained for WT1. The glomerular tuft areas are indicate the dotted lines. (g–j) Graphs showing
thenumberofWT1þ cells in theglomerular tuft (g), thenumberofWT1þ cells in theglomerular tuft normalized to theglomerular area (h), thenumber
ofWT1þ cells in the area of the glomerulus surrounding the glomerular tuft (i), and the number of WT1þ cells in the whole glomerulus (j). Cells were
counted as 50 glomeruli per sample, except in (h), where cells were counted and normalized to the glomerular area as 15 glomeruli per sample. Data
are presented as mean  SEM. Tmsb4xþ/y (n ¼ 5), Tmsb4þ/y þ NTS (n ¼ 9), and Tmsb4x/y þ NTS (n ¼ 6) mice. Bar ¼ 20 mm. Tmsb4x, thymosin b4.
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Figure 5 | Effects of downregulating endogenous Tmsb4x expression in podocytes in vitro. (a) Podocytes grown in vitro under permissive
conditionsweredifferentiated for 14days before transfecting themwith control siRNAor siRNA targetingTmsb4x. (b) Quantiﬁcationof Tmsb4xmRNA
levels in podocytes 48 hours after transfection. (c) Cell viability after knockdown of endogenous Tmsb4x was assessed by MTT assay. (d) Podocyte
migration after knockdown of endogenous Tmsb4xwas assessed by a wound-healing assay, and the number of cells that migrated into the wound
area was counted. (e) Representative images of podocytes transfected with control or Tmsb4x siRNA 0, 6, and 24 hours after wound formation.
Representative images showing a podocyte with cytoplasmic stress ﬁber F-actin distribution (f) or cortical F-actin distribution (g). The percentage of
cells with predominantly cytoplasmic stress ﬁbers or cortical actin formation was quantiﬁed 48 hours after transfection (h). Quantiﬁcation of active
RhoA (i) and active Cdc42 (j) 48 hours after transfection. All experiments were repeated 3 to 4 times, and the data are presented as mean  SEM.
*P# 0.05, ***P # 0.001. IFN-g, interferon-g; Lip, lipofectamine; OD, optical density; siRNA, small, interfering RNA; TB, Tmsb4x, thymosin b4.
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bas i c re sea r ch E Vasilopoulou et al.: Thymosin b4 and glomerular diseaseafter NTS administration, with increased numbers in both the
glomerular tuft and periglomerular area compared with
Tmsb4xþ/y mice with or without disease (P < 0.01)
(Figure 6i–m). mRNA levels of the pan-macrophage marker
Cd68 were also signiﬁcantly higher 21 days after NTS injection
in whole-kidney homogenates obtained from Tmsb4x/y
compared with Tmsb4xþ/y mice (Supplementary Figure S10A).
Cd68 is expressed by all macrophages, but these comprise a
diverse group that includes a broad spectrum of cellular
phenotypes, often characterized as pro-inﬂammatory (M1
type) and tissue repair (M2 type) macrophages. We quantiﬁed
the mRNA levels of M1 (Mcp1, Cd86) and M2 markers
(Cd206, Arg1) and found all of these genes were signiﬁcantly
upregulated in Tmsb4x/y mice compared with Tmsb4xþ/y
mice after NTS administration (Supplementary Figure S10B–
E). This suggests that there is a global increase in macrophages
in Tmsb4x/y kidneys after NTS rather than a shift toward an
M1 or M2 phenotype.
Finally, the increased accumulation of macrophages in the
periglomerular area in Tmsb4x/y mice with NTS was asso-
ciated with increased periglomerular ﬁbrosis, as shown by
increased staining for both collagen IV (Figure 7a–c) and
a-smooth muscle actin (Figure 7e–g) in sections from
Tmsb4x/y compared with Tmsb4xþ/y mice injected with NTS
along with increased whole-kidney mRNA levels of Col4a1
(P < 0.05) (Figure 7d) and Acta2 (P < 0.05) (Figure 7h).
DISCUSSION
In this study, we found endogenous Tmsb4x was not required
to maintain glomerular structure and function in healthy
adult mice. However, in an experimental model of NTS
nephritis, glomerular disease was exacerbated in mice lacking
Tmsb4x accompanied by changes in the distribution of
podocytes within the glomerulus, increased periglomerular
macrophage accumulation, and enhanced ﬁbrosis. These
ﬁndings provide the ﬁrst evidence that endogenous Tmsb4x
modiﬁes glomerular injury, likely having a protective role
acting as a brake to slow disease progression.
We showed that Tmsb4x is expressed in developing and
adult mouse glomeruli, predominantly localized to podocytes.
Previous studies also found Tmsb4x in glomerular podo-
cytes,25 but others reported the complete absence of Tmsb4x
in the glomeruli of human fetal and adult kidneys45 and rat
kidneys.26 These discrepancies may be due to differences in
the antibodies and ﬁxation methods used.46 Importantly, we
obtained similar results for both Tmsb4x mRNA and protein
and conﬁrmed the speciﬁcity of antibody staining using tissue
from Tmsb4x/y mice as an additional negative control.
Given that Tmsb4x plays a role in actin binding,6 we
initially hypothesized that the lack of endogenous Tmsb4x
might disrupt the highly branched architecture of glomerular
podocytes and impair renal function.3 However, the lack of
Tmsb4x did not affect glomerular morphology or podocyte
architecture of normal healthy mice in vivo. We found
upregulation of Cfn1, which severs actin ﬁlaments, in whole
Tmsb4x/y kidneys. This could partly compensate for the lack1064of Tmsb4x and maintain actin dynamics47; however, Cfn1 was
not speciﬁcally altered in podocytes lacking Tmsb4x, thus
making this unlikely.
A signiﬁcant ﬁnding of our study was that severity of
glomerular disease induced by NTS was greater in Tmsb4x/y
mice compared with wild-type littermates. We postulate that
endogenous Tmsb4x has a protective role in the setting of
NTS, a prediction supported by a study showing that exoge-
nous administration of Ac-SDKP ameliorated rat glomeru-
lonephritis.22 However, we found that whole-mouse kidney
Tmsb4x mRNA levels were unchanged with NTS nephritis,
and this was mirrored when we assessed TMSB4X mRNA
levels in glomerular and tubulointerstitial extracts from hu-
man kidneys affected by rapidly progressive glomerulone-
phritis or lupus nephritis. In contrast, a previous study in rat
remnant kidneys in which nephron loss results in focal
segmental glomerulosclerosis showed that Tmsb4x protein
levels were signiﬁcantly increased in sclerotic versus normal
glomeruli.26 The discrepancy between these ﬁndings may be
due to the different renal injury models and time points
examined.
There are likely to be multiple mechanisms by which the
lack of endogenous Tmsb4x results in increased glomerular
injury in our experimental model. During nephrotoxic
nephritis, podocytes switch from a terminally differentiated
cell to a migratory cell that forms bridges between the
glomerular tuft and the Bowman capsule34 and populates
glomerular crescents.30,48 The lack of Tmsb4x increased the
number of glomeruli with adhesion of the glomerular tuft to
the Bowman capsule and glomerular epithelial hyperplasia
lesions, a feature of early crescent formation in this model.34
We also found that there was a redistribution of podocytes
from the glomerular tuft, where they contribute to ﬁltration
barrier integrity toward the Bowman capsule. Our in vitro
data demonstrate that downregulation of endogenous Tmsb4x
in podocytes increases migration, and we predict that this
may promote their redistribution in the nephrotoxic nephritis
model. The increased podocyte migration was associated with
increased actin stress ﬁbers and activation of RhoA, which has
been linked to podocyte stress ﬁber formation.49,50 Moreover,
podocyte-speciﬁc overexpression of RhoA induces protein-
uria,50,51 whereas RhoA inhibition improves renal injury in
mouse models of nephrectomy52 and nephrotoxic nephritis,53
demonstrating the functional importance of this pathway in
glomerular function. Other studies have shown that RhoA
activation inhibits podocyte migration,54 but these experi-
ments used a constitutively active form of RhoA permanently
in the guanosine triphosphate-bound state. This would result
in a high degree of RhoA activity, which has been associated
with inhibition of migration.55 In contrast, Tmsb4x knock-
down led to a 2-fold upregulation of RhoA activity in
podocytes. It has been postulated that this lesser degree of
RhoA activation promotes contractile stress ﬁber formation,
facilitating cell detachment in migrating cells39 and enhancing
lamellipodia formation driving cell motility.55 It was previ-
ously reported that activation of other Rho GTPases, Cdc42Kidney International (2016) 90, 1056–1070
Figure 6 | Assessment of inﬂammation in nephrotoxic nephritis. Representative images of F4/80 (macrophages) (a) and thymosin b4
(Tmsb4x) staining (b). Cells positive for both F4/80 (green) and Tmsb4x (red) are shown in the merged image (c) and are indicated by arrows.
Images were taken by ﬂuorescent microscopy. Bar ¼ 20 mm. Representative images showing Cd3 (T-cell marker) staining in the glomerular tuft
(arrows) and in the periglomerular area (arrowheads) of Tmsb4xþ/y controls (d) and Tmsb4xþ/y (e) and Tmsb4x/y (f) mice 21 days after
administration of nephrotoxic serum (NTS). The number of Cd3þ cells in the glomerular tuft (g) and in the periglomerular area (h) was counted as
50 glomeruli per sample, and the average number was calculated (Tmsb4xþ/y, n¼ 5; Tmsb4xþ/yþ NTS, n¼ 9; Tmsb4x/yþ NTS, n¼ 6). (Continued)
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found that downregulation of endogenous Tmsb4x did not
affect Cdc42 activation in podocytes. Rac1 activity was not
assessed in this study, and it would be interesting to explore
its involvement in the future.
Tmsb4x is also expressed in macrophages,18,40 including in
our nephrotoxic nephritis model, but its precise function has
yet to be determined. It could be postulated that loss of the
macrophage Tmsb4x may regulate the actin cytoskeleton,
which has been implicated in both phenotypic polarization57
and migration.58 In our study, the loss of Tmsb4x did not alter
macrophage polarization or the number of activated macro-
phages found in the glomerular area in the early stages of
nephrotoxic nephritis. However, the number of activated
macrophages in the periglomerular area at the late stage of the
disease was increased in Tmsb4x/y mice, suggesting a deﬁ-
ciency in the resolution of inﬂammation resulting in persis-
tent macrophage accumulation. Macrophage accumulation
may result from an absence of the Tmsb4x-derivative
thymosin b4 sulfoxide, which has been shown to disperse
inﬂammatory macrophages at the injury site in zebraﬁsh and
mouse models of heart injury.59 We also found that peri-
glomerular ﬁbrosis was enhanced in Tmsb4x/y mice after
NTS administration compared with wild-type mice. This may
represent a secondary effect of enhanced inﬂammation and
glomerular damage. However, previous studies showed that
Tmsb4x can alter both plasminogen activator inhibitor-1 and
transforming growth factor-b1,
18,27 both of which are drivers
of ﬁbrosis and play important roles in the progression of
nephrotoxic nephritis.60,61
In summary, we have provided the ﬁrst evidence that the
lack of endogenous Tmsb4x does not affect healthy glomeruli
but exacerbates renal function impairment, periglomerular
inﬂammation, and ﬁbrosis in the context of nephrotoxic
nephritis. These ﬁndings suggest that modulating Tmsb4x
could be a potential therapeutic target in immune-mediated
glomerular disease.
METHODS
Experimental animals and procedures
C57Bl/6 hemizygous null male mice (Tmsb4x/y) were bred with
heterozygous Tmsb4xþ/ adult female mice to generate male wild-
type (Tmsb4xþ/y) and null mice.27 To induce glomerular disease,
Tmsb4þ/y and Tmsb4x/y mice were preimmunized by subcutaneous
injection of sheep IgG (250 mg) in complete Freund’s adjuvant,
followed by i.v. administration of sheep NTS (250 ml) 5 days later.62
All procedures were approved by the UK Home Ofﬁce.
Renal function
Urine was collected from mice by housing them individually in
metabolic cages. Blood samples were collected from the lateralFigure 6 | (Continued) Representative images showing F4/80 (activated m
periglomerular area of Tmsb4xþ/y control (i), Tmsb4xþ/yþ NTS (j), and Tmsb
(l) and in the periglomerular area (m) was counted as 50 glomeruli per s
Tmsb4xþ/y þ NTS, n ¼ 8; Tmsb4x/y þ NTS, n ¼ 6). Data are presented as m
thymosin b4.
1066saphenous vein. Albumin concentrations were measured by
enzyme-linked immunosorbent assay28,63 (Bethyl Laboratories,
Montgomery, TX). Urinary and plasma creatinine concentrations
were measured using isotope dilution electrospray mass spectrom-
etry.64 Creatinine clearance (ml/min per gram of body weight) was
derived from the formula urinary creatinine  urine volume  1440
min1  plasma creatinine1  body weight (g)1.63 Blood urea
nitrogen was assessed using a commercially available assay kit, vali-
dated in mice (BioAssay Systems, Hayward, CA).65
Histologic analysis and immunohistochemistry
Kidneys were ﬁxed in 4% paraformaldehyde and embedded in
parafﬁn, and 5-mm sections were cut and stained with periodic
acid–Schiff reagent. Fifty glomeruli per sample were scored by 2
blinded observers using the following system: 0, normal glomerular
structure; 1, increased mesangial matrix deposition and hyper-
cellularity with some loss of capillary loops; 2, increased matrix
deposition and focal areas of sclerosis; 3, >50% of glomerulus
sclerotic with very few capillary loops; 4, >75% of glomerulus
sclerotic and the presence of glomerular epithelial hyperplasia le-
sions (Supplementary Figure S5). An average score was obtained for
each kidney.
Immunohistochemistry or immunoﬂuorescence was performed66
using antibodies against Tmsb4x (A9520, Immundiagnostik, Ben-
sheim, Germany), collagen IV (ab19808, Abcam, Cambridge, UK),
Cd3 (ab16669, Abcam), a-smooth muscle actin (M0851, Dako, Ely,
UK), F4/80 (MCA497R, AbD Serotec, Oxford, UK), Nphs1 (GP-N2,
Progen, Heidelberg, Germany), nestin (NB100-1604, Novus Bi-
ologicals, Littleton, CO), WT1 (AP15857PU-S, Acris Antibodies,
Herford, Germany), Cd31 (MA3105, Thermo Fisher Scientiﬁc,
Waltham, MA), and sheep IgG (A11016, Thermo Fisher Scientiﬁc).
CD3þ and F4/80þ cells were counted in 50 glomeruli per sample. To
assess glomerular sheep IgG deposition, mean ﬂuorescence intensity
was measured using ImageJ67 (30 glomeruli/sample). The number of
WT1þ cells found within or outside (in glomerular crescents or
lining the Bowman capsule) the glomerular tuft was counted in 50
consecutive glomeruli per sample. To account for any changes in the
glomerular tuft area, the number of WT1þ cells in the glomerular
tuft was normalized to the glomerular area (measured using
ImageJ67) in 15 glomeruli per sample. Apoptosis was identiﬁed using
TUNEL (Roche, Burgess Hill, UK). The number of TUNELþ and
WT1þ/TUNELþ cells was counted in 50 glomeruli per sample.
Measurement of murine IgG subclasses speciﬁc for sheep IgG
The titers of murine IgG subclasses speciﬁc for sheep IgG were
measured by enzyme-linked immunosorbent assay in plasma, as
described,68 using alkaline phosphatase subclass-speciﬁc antibodies
for IgG1, IgG2b, and IgG3 (SouthernBiotech, Birmingham, AL) and
IgG2a (Bethyl Laboratories).
In situ hybridization
In situ hybridization on parafﬁn sections was performed as
described,27 using a digoxigenin-labeled antisense riboprobe speciﬁc
for the 30UTR of Tmsb4x, alongside a sense control.acrophage marker) staining in the glomerular tuft and the
4x/yþ NTS (k) mice. The number of F4/80þ cells in the glomerular tuft
ample, and the average number was calculated (Tmsb4xþ/y, n ¼ 5;
ean  SEM. *P# 0.05, **P # 0.01, ***P # 0.001. Bar ¼ 20 mm. Tmsb4x,
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Figure 7 | Assessment of ﬁbrosis in nephrotoxic nephritis. Representative images showing collagen IV staining in glomeruli of Tmsb4xþ/y (a),
Tmsb4xþ/y þ nephrotoxic serum (NTS) (b), and Tmsb4x/y þ NTS (c)mice. (d) Quantiﬁcation of collagen IV (Col4a1) mRNA levels in whole-kidney
homogenates of Tmsb4xþ/y (n ¼ 8), Tmsb4xþ/y þ NTS (n ¼ 9), and Tmsb4x/y þ NTS (n ¼ 6) mice. Representative images showing a-smooth
muscle actin (a-SMA) staining in glomeruli of Tmsb4xþ/y (e) Tmsb4xþ/y þ NTS (f) and Tmsb4x/y þ NTS (g) mice. (h) Quantiﬁcation of a-SMA
(Acta2) mRNA levels in whole-kidney homogenates of Tmsb4xþ/y (n ¼ 8), Tmsb4xþ/y þ NTS (n ¼ 8), and Tmsb4x/y þ NTS (n ¼ 5) mice. Data are
presented as mean  SEM. *P # 0.05, **P # 0.01. Bar ¼ 20 mm. Tmsb4x, thymosin b4.
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For transmission electron microscopy, kidney cortex specimens
(1 mm3) were postﬁxed in osmium tetroxide, dehydrated in acetone,
and embedded in epoxy resin. Ultrathin sections were stained with
uranyl acetate and lead citrate and examined.
Quantitative real-time polymerase chain reaction
RNAwas extracted from mouse whole-kidney or glomerular extracts
(isolated by Dynabeads [Thermo Fisher Scientiﬁc]28); 500 ng was
used to prepare cDNA (iScript kit, Bio-Rad, Hemel Hempstead, UK),
and quantitative real-time polymerase chain reaction was performed
as described28 with Hprt as a housekeeping gene. All measurements
were performed in duplicate. Renal biopsy specimens from patients
with rapidly progressive glomerulonephritis (n ¼ 12), lupus
nephritis (n ¼ 12), and living donor controls (n ¼ 7) were collected
within the framework of the European Renal cDNA Bank–Kroener–
Fresenius Biopsy Bank69 after informed consent and local ethics
committee approval. Unﬁxed tissue was transferred to RNase in-
hibitor and manually microdissected into glomerular and tubu-
lointerstitial compartments. Total RNA was isolated and quantitative
real-time polymerase chain reaction performed as reported,69 with
18S rRNA (Applied Biosystems, Foster City, CA) as the reference
gene. Primer details are available on request.
Cell culture
Mouse podocytes37 were cultured as described70 and allowed to
differentiate for 14 days. Cells were transfected with 10 nM siRNA
speciﬁc for Tmsb4x or with a nontargeting control (both from Santa
Cruz Biotechnology, Dallas, TX) using the transfection reagent
Lipofectamine RNAiMAX (Thermo Fisher Scientiﬁc) according to
the manufacturer’s instructions.
Cell viability was assessed 24, 48, and 72 hours post-transfection
using the methyltetrazolium assay. To assess migration, podocytesKidney International (2016) 90, 1056–1070were plated to conﬂuence, and a scratch was created using a pipette
tip. Images (4 ﬁelds per condition) were taken 0, 6, and 24 hours
later and the number of cells that migrated into the wound area
counted. To visualize F-actin ﬁlaments 48 hours post-transfection,
podocytes were ﬁxed in 4% paraformaldehyde and 4% sucrose
and stained with AlexaFluor-594 phalloidin (Thermo Fisher Sci-
entiﬁc). The arrangement of actin ﬁlaments (either cytoplasmic
stress ﬁbers or cortical actin) was assessed in 30 cells per condition.
RhoA and Cdc42 activity was quantiﬁed in podocyte lysates by
G-LISA Small G-protein Activation Assays (Cytoskeleton, Denver,
CO).
Glomeruli from Tmsb4xþ/y and Tmsb4x/y mice were isolated
by Dynabeads (Thermo Fisher Scientiﬁc)28 and cultured in
Matrigel-coated plates (Corning, Tewksbury, MA) in Dulbecco’s
modiﬁed Eagle’s medium:F12 with 10% fetal calf serum, 1%
Insulin-Transferrin-Selenium, and 100 mg/ml penicillin (Thermo
Fisher Scientiﬁc). On day 7, when podocytes had grown out of the
glomeruli, they were detached using trypsin–ethylenediamine
tetraacetic acid and separated from glomeruli using 40-mm cell
strainers (Corning). Primary podocytes obtained with this
method were >90% pure, as judged by cell morphology and
staining using podocyte (nephrin, nestin) markers.
Statistical methods
All samples were assessed blinded to treatment. Data are presented as
mean  SEM and were analyzed using GraphPad Prism (GraphPad
Software, La Jolla, CA). When differences between 2 groups were
evaluated, data were analyzed using a t test. When $3 groups were
assessed, 1-way analysis of variance with Bonferroni’s multiple
comparison post hoc tests were used. Data affected by 2 variables
were analyzed using 2-way analysis of variance with Bonferroni’s
multiple comparison post hoc tests. Statistical signiﬁcance was
accepted at P # 0.05.1067
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Figure S1. Representative images of nestin (A) and Tmsb4x (B)
staining in the mouse adult wild-type glomerulus visualized by ﬂuo-
rescent microscopy. (C) Merged images showing Tmsb4x (red) and
nestin (green) staining; areas of colocalization are indicated by
arrows. Representative images of Tmsb4x (D) and Cd31 (E) staining in
the mouse adult wild-type glomerulus visualized by ﬂuorescent mi-
croscopy. (F) Merged images showing Tmsb4x (green) and Cd31 (red)
staining. Bar ¼ 20 mm.
Figure S2. Quantiﬁcation of proﬁlin 1(Pfn1) (A), proﬁlin 2 (Pfn2) (B),
destrin (Dstn) (C), and coﬁlin 1 (Cﬂ1) (D) mRNA in whole-kidney ho-
mogenates of Tmsb4xþ/y (n ¼ 8) and Tmsb4x/y (n ¼ 4) mice by
quantitative reverse transcriptase polymerase chain reaction. Quan-
tiﬁcation of coﬁlin 1 (Cﬂ1) mRNA in podocytes 48 hours after trans-
fection with control siRNA or siRNA targeting Tmsb4x (n ¼ 4) (E) and
in podocytes isolated from Tmsb4xþ/y or Tmsb4x/y mice (n ¼ 6) (F).
Data are presented as mean  SEM. *P < 0.05.
Figure S3. Quantiﬁcation of nephrin (Nphs1; A), podocin (Nphs2; B),
synaptopodin (Synpo; C), cd2 associated protein (Cd2ap) (D) and
Wilms tumor 1 (Wt1) (E) mRNA in whole-kidney homogenates of
Tmsb4xþ/y (n ¼ 8) and Tmsb4x/y (n ¼ 4) mice by quantitative reverse
transcriptase polymerase chain reaction. Data are presented as mean
 SEM.
Figure S4. (A) Quantiﬁcation of Tmsb4x mRNA levels in whole-kidney
homogenates of Tmsb4xþ/y (n ¼ 8) and Tmsb4xþ/y þ NTS (n ¼ 9) mice
by quantitative reverse transcriptase polymerase chain reaction.
(B and C) Quantiﬁcation of TMSB4X mRNA levels in homogenates
from human glomeruli (B) or tubulointerstitium (C). LD, living donor;
RPGN, rapidly progressive glomerulonephritis; SLE, lupus nephritis.
Data are presented as mean  SEM.
Figure S5. Representative images of the histology observed 7 days
after NTS administration showing a normal glomerulus (A), a
glomerulus with hyaline deposits indicated by arrowheads (B), and a
glomerulus with a bridge formed between the glomerular tuft and
the Bowman capsule indicated by an arrow (C). Bar ¼ 20 mm.
Figure S6. Representative images of the different scoring categories
for glomerular injury showing a normal glomerulus, score 0 (A); a
glomerulus with increased mesangial matrix deposition and some
loss of capillary loops, score 1 (B); a glomerulus with increased
mesangial matrix deposition and focal areas of sclerosis, score 2 (C); a
glomerulus with >50% sclerotic area and very few capillary loops,
score 3 (D); and a sclerotic glomerulus with an epithelial hyperplastic
lesion (*) and a bridge formed between the glomerular tuft and
the Bowman capsule indicated by an arrow, score 4 (E). Bar ¼ 20 mm.1068(F) Proportions of glomeruli in the different scoring categories of
glomerular injury in Tmsb4xþ/y (n ¼ 5), Tmsb4xþ/y þ NTS (n ¼ 9), and
Tmsb4x/y þ NTS (n ¼ 6) mice. Bars represent the mean  SEM.
Figure S7. Representative images showing sheep IgG
immunoreactivity in glomeruli of Tmsb4xþ/y (A) and Tmsb4x/y (B)
mice injected with nephrotoxic serum (NTS). (C) Quantiﬁcation of
mean ﬂuorescence in 30 glomeruli per sample (Tmsb4þ/y þ NTS,
n ¼ 9; Tmsb4x/yþ NTS, n ¼ 6). Plasma titers of murine IgG subclasses
(D, IgG1; E, IgG2a; F, IgG2b; G, IgG3) against sheep IgG in control,
not immunized Tmsb4xþ/y mice (n ¼ 5) and in Tmsb4xþ/y (n ¼ 9)
and Tmsb4x/y (n ¼ 6) mice 21 days after NTS injection. Data are
presented as mean  SEM. Bar ¼ 20 mm, *P # 0.05, ** P # 0.01,
*** P # 0.001.
Figure S8. Representative image showing staining for TUNEL (A) and
WT-1 (B) in the glomerulus. A TUNEL-positive podocyte is identiﬁed
by an arrowhead (C). The number of TUNEL-positive cells (D) and
TUNEL-positive WT-1–positive cells per glomerulus was counted in 50
glomeruli per sample, and the average number was calculated
(Tmsb4xþ/y, n ¼ 4; Tmsb4xþ/y, þ NTS, n ¼ 9; Tmsb4x/y þ NTS, n ¼ 6).
Data are presented as mean  SEM. Bar ¼ 20 mm. *P # 0.05.
Figure S9. The number of F4/80þ cells in the glomerular tuft (A) and in
the periglomerular area (B) 7 days after administration of nephrotoxic
serum (NTS) was counted in 50 glomeruli per sample, and the average
number was calculated (Tmsb4xþ/y, n ¼ 5; Tmsb4xþ/y þ NTSþ, n ¼ 6;
Tmsb4x/y þ NTS, n ¼ 8). Data are presented as mean  SEM.
**P # 0.01.
Figure S10. Quantiﬁcation of Cd68 (A), Mcp1 (B), Cd86 (C), Cd206 (D),
and Arg1 (E) mRNA in whole-kidney homogenates of Tmsb4þ/y þ NTS
(n ¼ 9) and Tmsb4x/y þ NTS (n ¼ 6) mice. NTS ¼ nephrotoxic serum.
Table S1. Proportions of Tmsb4xþ/, Tmsb4x/, Tmsb4xþ/y, and
Tmsb4x/y mice born after crossing adult male Tmsb4x/y mice with
Tmsb4xþ/ adult female mice.
Supplementary material is linked to the online version of the paper at
www.kidney-international.org.
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